May 1, 2023 4:52pm
Seven (7) Q1 LPS (loss-per-share) earnings releases coming this week, post session reporting could begin with a wavering sector response
Listing Update: Verastem Oncology (VSTM) 198 sessions under the Nasdaq $1.00 minimum pricing
Pre-Open Indications: 5 Hits and 1 Miss
I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about - truth!
Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
Skim if you can trim, buy if it will fly and sell if compelled!
If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed DOWN -46.46 points (-0.14%), the S&P closed DOWN -1.61 points (-0.04%) while the Nasdaq closed DOWN -31.99 points (-0.11%)
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies.
Indexes dived Monday amid the banking crisis response.
Over the weekend, the government seizure of First Republic and sale to JPMorgan Chase slowing the backing environment scare.
Economic Data Docket: Manufacturing activity in the U.S. contracted for a sixth (6th) straight month in April, though by less than expected. The ISM Manufacturing PMI came in at 47.1%, representing the share of companies reporting expansion for the month. That was higher than the 46.3% in March and better than the 46.7% estimate. <the Institute for Supply Management>
Monday (5/1) … RegMed Investors’ (RMi) pre-open: “share pricing trouble coming, just a matter of when?” … https://www.regmedinvestors.com/articles/12938
Pre-Open Indications: 5 Hits < Agenus (AGEN +$0.005), Intellia Therapeutics (NTLA $0.01), Chinook Therapeutics (KDNY -$0.17), Avrobio (AVRO -$0.1596), CRISPR Therapeutics (CRSP +$0.14)> 1 Miss < Regenxbio (RGNX +$0.74)>
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …
- Monday’s advance/decline line opened positive at 28 up/ 5 down and 2 flats, stayed positive with 29 up/ 4 down and 2 flats at the mid-day, ending with a positive close of 26/7 and 2 flats
Key Metrics:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Monday, the IBB was up +0.79% and the XBI was up +2.42%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Monday was up +0.29 points or +1.84% at 16.07
Closing Down (7 of 7):
- Sage Therapeutics (SAGE -$0.43),
- Chinook Therapeutics (KDNY -$0.17),
- Avrobio (AVRO -$0.1596),
- Precigen (PGEN -$0.03),
- Homology Medicine (FIXX -$0.015),
- Voyager Therapeutics (-$0.01),
- Intellia Therapeutics (NTLA -$0.01)
Flat (2):
- Agenus (AGEN)
- Biostage (OTCQB: BSTG)
Closing Up (10 of 26):
- Alnylam Pharmaceuticals (ALNY +$2.67),
- Regenxbio (RGNX +$0.74),
- Vericel (VCEL +$0.71),
- uniQure NV (QURE +$0.70),
- Solid Biosciences (SLDB +$0.41),
- Ultragenyx (RARE +$0.36),
- Ionis Pharmaceuticals (IONS +$0.31),
- Fate Therapeutics (FATE +$0.29),
- AxoGen (AXGN +$0.25),
- Prime Medicine (PRME +$0.24),
Q2/23 – May
- Monday closed positive with 26 incliner, 7 decliners and 2 flats
The BOTTOM LINE: I try to keep it simple … and short!
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
Ask yourself, do you know why you own certain equity? What’s been communicated re a company’s status at any given time to shareholders other than quarterly reports or a once-upon-a-time press release!
There are clear winners — and losers — at the start of May. The top three performing are:
· Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Regenxbio (RGNX).
While The worst three (3):
· Sage Therapeutics (SAGE), Chinook Therapeutics (KDNY). Avrobio (AVRO),
Earnings:
Sangamo Therapeutics (SGMO) could NOT recognize their quarterly numbers of net loss and per share loss but could identify its cash position – NOT quite the bell weather for the sector as even preliminary numbers were NOT available – WRONG measure of defining expectation!
Mesoblast (MESO) Q3/23 NO Q (even in SEC filed 6K) information while reporting $48.8 M in cash with an additional debt financing in place.
WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.
I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.
The NO spin zone! Do not U.S. public shareholders deserve accountability …
De-Listing Update:
Avrobio (AVRO) - Monday closed down -$0.01596 to $0.83 as CEO Geoff MacKay resigned; still under Nasdaq minimum rule of $1.00; after twenty (20) sessions
· Will AVRO do a reverse split to upend delisting to “SCREW” shareholders yet, AGAIN?
Verastem Oncology (VSTM) one hundred ninety-eight (198) sessions under the Nasdaq $1.00 minimum pricing
Biostage (OTCQB: BSTG) … question of viability
· Monday closed FLAT with 0 shares traded after Friday closed FLAT with 0 shares traded, Thursday closed flat with 0 shares traded, Wednesday closed flat with 27 shares traded, Tuesday closed FLAT with only 15 shares traded and last Monday closed down -$0.07 with 600 shares traded <3-month average =1,613 shares>
· Question: Review the number of shares traded … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?
My question that resounds, that should be asked is how many companies are at the end of sentiments … leash?
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
